Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome

Revista Portuguesa de Cardiologia

Volumn 29, Issue 10, 2010, Pages 1511-1520

  Gaspar, António ^a   Ribeiro, Sílvia ^a   Nabais, Sérgio ^a   Rocha, Sérgia ^a   Azevedo, Pedro ^a   Pereira, Miguel Álvares ^a   Brandão, Aida ^a   Salgado, Alberto ^a   Correia, Adelino ^a  

^a HOSPITAL DE BRAGA   (Portugal)

Author keywords

Acute coronary syndrome; Antiplatelet therapy; Clopidogrel; Prognosis; Proton pump inhibitor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PANTOPRAZOLE; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROGNOSIS; TREATMENT DURATION;

ACUTE CORONARY SYNDROME; AGED; ASPIRIN; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; TICLOPIDINE;

EID: 78751693249     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Steinhubl SR, Berger PB, Mann JT III, et al; CREDO investigators. Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention. A Randomized Controlled Trial. JAMA 2002; 288:2411-2420.
2. CURE investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502.
3. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-21.
4. Savi P, Herbert JM, Pflieger AM, et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 1992; 44: 527-32.
5. Kim KA, Park PW, Hong SJ, et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance. Clin Pharmacol Ther 2008; 84: 236-42.
6. Gilard M, Arnaud B, Le Gal G, Abgrall JF, Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Hemost 2006; 4: 2508-09. (Pubitemid 44575451)
7. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51: 256-60.
8. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Hemost 2009; 101: 714-19.
9. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009; 180: 713-18.
10. Ho PM, Maddox TM, Wang L, et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009; 301: 937-44.
11. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: the Clopidogrel Medco Outcomes Study. Paper presented at: SCAI 32nd Annual Scientific Sessions. Las Vegas, NV, 2009.
12. Dunn SP, Macaulay TE, Brennen DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118: 815A (abstract).
13. Michelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, Sabina A Murphy, Eric R Bates, Yoseph Rozenman, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet 2009; 374: 989-97.
14. Bhatt D, Cryer B, Contant C, Cohen M, Lanas A, Schnitzer T et al.; on behalf of the COGENT Investigators. The COGENT Trial. Paper presented at: The 21st Annual Transcatheter Cardiovascular Therapeutics Conference. San Francisco, 2009.
15. Li XQ, Andersson TB, Ahlstrom M, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32:821-7.
16. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 2003; 107: 32-37.
17. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003; 108: 921-24. (Pubitemid 37048218)
18. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003; 92: 285-88.
19. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton-pump inhibitors. http://www.emea.europa.eu/ humandocs/PDFs/EPAR/Plavix/32895609en.pdf (accessed July 23, 2009).
20. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). http://www.fda.gov/cder/ drug/early-comm/clopidogrel-bisulfate.htm (accessed July 23, 2009).